Shanghai Henlius Biotech, Inc. announced that its first self-developed innovative PD-1 inhibitor HANSIZHUANG has been approved by the National Medical Products Administration (NMPA) for...
NeuroSense Therapeutics Ltd. ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced it has received proceeds of approximately $4 million from the exercise...
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that NVX-CoV2373, its protein-based COVID-19 vaccine, is...
MoonLake Immunotherapeutics AG ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, announced that it is proceeding with a global...
